Beth Faiman, PhD, CNP

home / authors / beth-faiman-phd-cnp

Articles

Beth Faiman, CNP, PhD, an expert on multiple myeloma

Patient Profile 1: Managing CRS Following CAR T-Cell Therapy

Beth Faiman, PhD, CNP;Louis Williams, MD;Donna Catamero, ANP-BC, OCN, CCRC;Tiffany Richards, PhD, ANP-BC

June 12th 2024

Beth Faiman, CNP, PhD, presents the case of a 76-year-old woman with multiple myeloma who experienced cytokine release syndrome (CRS) following CAR T-cell therapy.

A panel of 4 experts on multiple myeloma

Navigating CAR T-Cell Therapy in Multiple Myeloma: A Collaborative, Patient-Centered Approach

Beth Faiman, PhD, CNP;Louis Williams, MD;Donna Catamero, ANP-BC, OCN, CCRC;Tiffany Richards, PhD, ANP-BC

June 5th 2024

Experts on multiple myeloma discuss how they educate and prepare patients who are going to receive CAR T-cell therapy and provide clinical insights on transitioning patients to community practices following treatment.

Unique Challenges in Managing Adverse Events Associated with CAR T-Cell Therapy

Beth Faiman, PhD, CNP;Louis Williams, MD;Donna Catamero, ANP-BC, OCN, CCRC;Tiffany Richards, PhD, ANP-BC

June 5th 2024

A panel of experts on multiple myeloma give an overview of unique challenges in managing adverse effects associated with CAR T-cell therapy as compared with other cancer therapies.

Key Takeaways from Health Care Systems on the Role of Bispecifics in MM

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

July 5th 2023

The panel closes their discussion by highlighting crucial takeaways about the use of bispecific antibodies in the treatment of multiple myeloma.

Future Perspectives on the Role of Bispecifics in MM

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

July 5th 2023

Doctors discuss the potential of bispecific therapies being used in earlier lines of treatment for multiple myeloma, and the need for understanding and reducing toxicities as much as possible.

Choosing Between BCMA and Non-BCMA Bispecifics in Multiple Myeloma Treatment

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

June 28th 2023

Experts explain the strategies for optimal selection between different BCMA-targeting and non-BCMA-targeting bispecifics for the treatment of relapsed/refractory multiple myeloma.

Sequencing BCMA-Targeting Bispecifics in R/R MM Treatment

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

June 28th 2023

Cindy Varga, MD, details her experience with sequencing BCMA-targeting agents for patients with relapsed/refractory multiple myeloma.

Managing Infections and Other Toxicities Associated with Bispecifics in MM

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

June 21st 2023

Jeremy Larsen, MD, discusses the management of infections, neurotoxicity, and other side effects associated with bispecifics in patients with R/R MM, including the need for prophylactic antimicrobials and monitoring of immunoglobulin levels.

Best Practices for Transition of Care in Patients with MM on Teclistamab

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

June 21st 2023

Expert panelists in multiple myeloma share their experiences with implementing bispecifics and transition of care in the community setting for patients with R/R MM.

Step-up Dosing and Monitoring in Patients with MM on Bispecifics: Health System Perspectives

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

June 14th 2023

The panel discusses the approach to step-up and treatment dosing for bispecifics in their respective health care systems.

Incorporating Teclistamab in R/R MM: Insights from Clinical Practices Across the US

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

June 14th 2023

Expert hematologist-oncologists discuss how they incorporate teclistamab in their clinical practice as well as variations in access to bispecifics and CAR T-cell therapy.

FCRH5-Targeting and Other Emerging Bispecifics in R/R MM

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

June 7th 2023

Jeremy Larsen, MD, discusses data from a phase 1/2 study of cevostamab and other emerging bispecifics being evaluated in patients with relapsed/refractory multiple myeloma.

MonumenTAL-1: Evaluating the Anti- GPRC5D-Targetings Bispecific in R/R MM

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

June 7th 2023

Dr Jeremy Larsen reviews data from the MonumenTAL-1 study investigating the CD3- and GPRC5D-targeting bispecific antibody talquetamab in relapsed/refractory multiple myeloma.

Data Updates on BCMA-Targeting Bispecific Antibodies in R/R MM Treatment

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

May 31st 2023

Dr Cindy Varga discusses recent data on the FDA-approved agent teclistamab, a bispecific antibody for patients with relapsed/refractory multiple myeloma.

$Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)$

Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

May 31st 2023

Binod Dhakal, MD, MS, discusses the management of relapsed multiple myeloma and the various treatment options available.

<1 2